Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.

Kao CJ, Wurz GT, Schröder A, Wolf M, Degregorio MW.

Oncoimmunology. 2013 Oct 1;2(10):e26285. Epub 2013 Sep 12.


Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team..

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.


Tecemotide: an antigen-specific cancer immunotherapy.

Wurz GT, Kao CJ, Wolf M, DeGregorio MW.

Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836. Review.


Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.

Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA.

Ann Oncol. 2015 Jun;26(6):1134-42. doi: 10.1093/annonc/mdv104. Epub 2015 Feb 26.


Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.

Wurz GT, Gutierrez AM, Greenberg BE, Vang DP, Griffey SM, Kao CJ, Wolf M, DeGregorio MW.

J Transl Med. 2013 Mar 13;11:64. doi: 10.1186/1479-5876-11-64.


Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Rossmann E, Österborg A, Löfvenberg E, Choudhury A, Forssmann U, von Heydebreck A, Schröder A, Mellstedt H.

Hum Vaccin Immunother. 2014;10(11):3394-408. doi: 10.4161/hv.29918.


L-BLP25: a peptide vaccine strategy in non small cell lung cancer.

Sangha R, Butts C.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4652-4. Review.


Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.

DeGregorio M, Soe L, Wolf M.

J Thorac Dis. 2014 Jun;6(6):571-3. doi: 10.3978/j.issn.2072-1439.2014.05.15. No abstract available.


INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.

Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T.

BMC Cancer. 2011 Oct 7;11:430. doi: 10.1186/1471-2407-11-430.


Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

Stinchcombe TE, Bogart JA.

Oncologist. 2012;17(5):682-93. doi: 10.1634/theoncologist.2012-0020. Epub 2012 Apr 24. Review.


Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M.

J Clin Oncol. 2005 Sep 20;23(27):6674-81.


Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.

Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Beier F, Falk M, Murray N.

J Cancer Res Clin Oncol. 2011 Sep;137(9):1337-42. doi: 10.1007/s00432-011-1003-3. Epub 2011 Jul 9.


A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.

Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulières D.

Clin Lung Cancer. 2010 Nov 1;11(6):391-5. doi: 10.3816/CLC.2010.n.101.


Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, De Ruysscher D, Belka C, Cordes S, Hepp R, Lütke-Brintrup D, Lehmann N, Schuler M, Jöckel KH, Stamatis G, Stuschke M.

J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.


L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Xia W, Wang J, Xu Y, Jiang F, Xu L.

J Thorac Dis. 2014 Oct;6(10):1513-20. doi: 10.3978/j.issn.2072-1439.2014.08.17. Review.


Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.

Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R Jr, Livingston RB, Griffin BR, Benfield JR.

J Thorac Cardiovasc Surg. 1993 Jan;105(1):97-104; discussion 104-6.


Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.

Kao CJ, Wurz GT, Monjazeb AM, Vang DP, Cadman TB, Griffey SM, Wolf M, DeGregorio MW.

Cancer Immunol Res. 2014 Jun;2(6):581-9. doi: 10.1158/2326-6066.CIR-13-0205. Epub 2014 Mar 10.


Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H.

Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.


Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.

Ohyanagi F, Horai T, Sekine I, Yamamoto N, Nakagawa K, Nishio M, Senger S, Morsli N, Tamura T.

Jpn J Clin Oncol. 2011 May;41(5):718-22. doi: 10.1093/jjco/hyr021. Epub 2011 Mar 9.


Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?

Berman AT, Simone CB 2nd.

Transl Lung Cancer Res. 2016 Feb;5(1):138-42. doi: 10.3978/j.issn.2218-6751.2016.01.11.

Supplemental Content

Support Center